Porton(SZ:300363) Zheng Quan Ri Bao·2025-08-28 08:14Core Viewpoint - The company reported a revenue of 1.621 billion yuan in the first half of 2025, with a strong performance in its core small molecule API business, which accounted for 93% of total revenue, showing a year-on-year growth of approximately 20% [2] Group 1: Business Performance - The core business segment maintained good growth, with the small molecule API business being the primary contributor [2] - New business segments, including small molecule formulations, gene and cell therapy, and new molecules, accounted for 7% of total revenue, with a year-on-year growth of about 22% [2] - The small molecule formulation business experienced a year-on-year revenue decline of 7%, primarily due to the impact of centralized procurement policies, leading to a decrease in market demand for domestic generic drug formulation CDMO services [2] Group 2: Strategic Outlook - The company aims to balance short-term business growth with long-term development by aligning with industry trends and market developments [2]